T

S

TOLANEY , Sara M

Last name: TOLANEY

First name: Sara M

2022 (v1)

Publication

Metadata-only

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Johnston, Stephen R D Toi, Masakazu O'Shaughnessy, Joyce

Background: Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2; also known as ERBB2)-negative, node-positive, high-risk, early breast cancer. Here, we report...

Uploaded on: February 11, 2024